Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs). As the most abundant internal modification of ...

Fat mass and obesity-associated protein is overexpressed in HCC and is associated with poor clinical outcomes. Mechanistically, FTO promotes HCC progression by stabilizing BUB1 mRNA through an m6A-YTH ...

Image Caption: The molecular mechanism of m6A methylation. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular ...

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny chemical modification in RNA, known as m6A, plays a critical role in the ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.